Fig. 1

AL002 phase 1 study design. Cohorts A through C sequentially enrolled 3 HVs into 3 single-participant cohorts treated with AL002 0.003 mg/kg, 0.03 mg/kg, or 0.2 mg/kg. For Cohorts D through I, 8 HVs (6 active: 2 placebo) were sequentially enrolled and treated with single doses of AL002 or placebo, at the following dose levels: 0.6 mg/kg, 2 mg/kg, 6 mg/kg, 15 mg/kg, 30 mg/kg, and 60 mg/kg. In addition, 2 open-label single-dose cohorts were enrolled: Cohort K enrolled 6 participants treated at 45 mg/kg, and Cohort N enrolled 8 participants treated at 60 mg/kg with CSF sampled at later timepoints. CSF, cerebrospinal fluid; HV, healthy volunteer; PD, pharmacodynamic; PK, pharmacokinetic; RND, randomization